Teva Reports First Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Teva Pharma (TEVA) Tops Q1 EPS by 17c, Revenues Beat; Offers FY20 EPS/Revenue Guidance
May 7, 2020 7:05 AM EDTTeva Pharma (NYSE: TEVA) reported Q1 EPS of $0.76, $0.17 better than the analyst estimate of $0.59. Revenue for the quarter came in at $4.4 billion versus the consensus estimate of $4.15 billion.
Revenues of $4.4 billionGAAP diluted EPS of $0.06Non-GAAP diluted EPS of $0.76Free cash flow of $551 millionMr. KÃ¥re Schultz, Teva's President and CEO, said, 2020 brought an unprecedented global health crisis, affecting all nations and industries, including the pharmaceutical industry, which plays many... More
